Grail says FDA advisory panel meets Sept. 23 on Galleri test PMA review

PUBT · 3d ago
Grail says FDA advisory panel meets Sept. 23 on Galleri test PMA review
  • Grail faces an FDA advisory committee review on Sept. 23, 2026 for its Galleri multi-cancer early detection blood test PMA.
  • The PMA was submitted on Jan. 29, 2026. The FDA granted Galleri Breakthrough Device designation in 2018.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grail Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608071105PR_NEWS_USPR_____LA18073) on August 07, 2026, and is solely responsible for the information contained therein.